Pascal Winnen

We are a start-up accelerator founded through a partnership between BLKB, the largest Bank in the Basel area and Launchpad, a global private equity firm. We seek the most promising innovative companies and help them grow through our accelerator programs, where we offer hands-on mentoring, specialized services, and access to funding. We run our accelerator programs in a state-of-the-art 4,000 m² innovation hub and co-working space called The 5th Floor in Muttenz.  InQbator works closely with the “100 fürs Baselbiet” (1004BB) program which is an initiative by BLKB, FHNW, and Baselland to offer financing to innovative SMEs and startups in the region for their next stage of growth. We offer mentorship and business services to selected 1004BB winners and also prepare companies in our program to stand their best chance at securing the 1004BB financing.

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. The company’s artificial intelligence-enhanced diagnostic profiles provide a solid basis to monitor mental well-being and enable advances in medical diagnoses. EvokAI deploys machine learning models to search medical data, integrate novel medical devices, and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses.

GeneLook AG GeneLook is creating the future of patient-centric medicine. GeneLook is the first company to address a market gap by providing an integrative solution to allow individuals to control and leverage their genetic data in order to optimize their own personal health/wellness journey, as well as add value to the entire healthcare ecosystem.

Sleepiz AG (Ltd.) is a Zürich based startup with a mission to provide patient-centric disease management through seamless integration of contactless monitoring into people’s homes. Sleepiz leverages the power of sleep insights with a device that is simply placed next to the bed. The device operates in a non-contact fashion and measures movements originating from heart contractions and breathing patterns, as well as body motions with medical grade accuracy. While currently focusing on respiratory illnesses, Sleepiz aims to improve people’s lives by creating the future of healthcare. By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence, in the future Sleepiz will not only be able to diagnose sleep disorders but also perform long-term monitoring. Thereby, the progression of chronic diseases will be monitored to allow faster intervention and better treatment. The company collaborates closely with leading clinics in Switzerland and Europe. Headquartered in Zürich, Switzerland, Sleepiz AG also has its own subsidiary in Pune, India. Within 6 years, the ETH spin-off has grown to a team of PhDs in engineering, data modelling and signal processing, as well as business and healthcare professionals. Sleepiz is touching lives without touching.

At BioReperia, we’re transforming how cancer therapies are developed and personalized. With over 55 years of world-renowned combined experience in zebrafish tumor models, and 10 years since our companys founding, our team delivers deep scientific expertise through the ZTX® platform – a fast, reliable, and CE-certified in vivo system that provides actionable results in just five days. Backed by strong validation and trusted by pharma, biotech, and clinicians, ZTX® offers a uniquely powerful, highly predictive, and cost-effective tool that provides high-resolution evaluation of tumor regression, metastasis inhibition, and immune interactions – using cell lines, PDX models, or patient-derived material. Whether youre developing small molecules or biologics, our platform empowers confident, data-driven decisions throughout the drug development pipeline. ZTX® PREDICT: Match patients with the most effective therapies to drive personalized oncology. ZTX® ONCOLEADS: Accelerate early discovery and strengthen preclinical programs with rapid, translatable efficacy data. By bridging human tumor biology with the speed and precision of ZTX® we help reduce R&D attrition, cut timelines, and increase clinical success. Let’s bring better cancer treatments to patients faster! Get in touch at info@bioreperia.com | www.bioreperia.com

Annaida Technologies, founded in 2019, is Swiss a high-tech stratup offering micro-NMR solutions for R&D and In Vitro Fertilization. Our technology, developed over years, demonstrates every day performance that redefine the state of art and allow to measure what is currently out of reach for the conventional instrumentation.

True precision medicine through single-cell science. Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human's hidden "single-cell"​ secrets. The performance and clinically-relevant application of Scailyte's platform ScaiVision have been demonstrated in numerous clinical projects that resulted in patent-pending biomarkers. Scailyte has a growing pipeline of clinical projects in immunology, oncology and women's health supported by top clinicians and access to high quality proprietary datasets. If you want to partner with us and save lives by enabling precision medicine, reach out to contact@scailyte.com More information about our company, technology & services you can find on our website - https://scailyte.com

HEMEX is a CRO providing clinical services to European biotech and medtech companies, assisting them throughout the clinical development process to ensure that products reach the market swiftly. Located in the Basel region, a major life sciences hub, and with offices in Germany, Benelux, and the United States, we are well positioned to serve small and medium enterprises (SMEs) with multinational clinical projects. The comprehensive package of services we provide includes clinical operations, quality management, regulatory guidance, grant writing services, and fundraising options. At HEMEX, we guarantee fast and clear communication, local accessibility, and transparency to meet the objectives of our clients.

We are a start-up accelerator founded through a partnership between BLKB, the largest Bank in the Basel area and Launchpad, a global private equity firm. We seek the most promising innovative companies and help them grow through our accelerator programs, where we offer hands-on mentoring, specialized services, and access to funding. We run our accelerator programs in a state-of-the-art 4,000 m² innovation hub and co-working space called The 5th Floor in Muttenz.  InQbator works closely with the “100 fürs Baselbiet” (1004BB) program which is an initiative by BLKB, FHNW, and Baselland to offer financing to innovative SMEs and startups in the region for their next stage of growth. We offer mentorship and business services to selected 1004BB winners and also prepare companies in our program to stand their best chance at securing the 1004BB financing.

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. The company’s artificial intelligence-enhanced diagnostic profiles provide a solid basis to monitor mental well-being and enable advances in medical diagnoses. EvokAI deploys machine learning models to search medical data, integrate novel medical devices, and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses.

GeneLook AG GeneLook is creating the future of patient-centric medicine. GeneLook is the first company to address a market gap by providing an integrative solution to allow individuals to control and leverage their genetic data in order to optimize their own personal health/wellness journey, as well as add value to the entire healthcare ecosystem.